In vivo visualization of a-synuclein deposition by [11C]BF-227 PET in Parkinson's disease and Parkinsonian syndrome

In vivo visualization of a-synuclein deposition by [11C]BF-227 PET in Parkinson's disease and Parkinsonian syndrome - In vivo visualization of a-synuclein deposition by [11C]BF-227 PET in Parkinson's disease and Parkinsonian syndrome

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017335

Enrollment

Registered

2015-04-30

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

Duration: from September, 2012 to August, 2022 Dose: about 333MBq of [11C]BF-227

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnostic criteria of Ministry of Health, Labour and Welfare

Exclusion criteria

Exclusion criteria: Patients with severe cardiac, renal, or liver diseases Patients with pregnancy or breast-feeding

Design outcomes

Primary

Measure	Time frame
High uptake of BF-227 by PET image	—

Countries

Japan

Contacts

Public ContactAkio Kikuchi

Tohoku University Graduate School of Medicine Department of Neurology

akikuchi@med.tohoku.ac.jp022-717-7189

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

In vivo visualization of a-synuclein deposition by [11C]BF-227 PET in Parkinson&#39;s disease and Parkinsonian syndrome